IRWD SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 26, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 10, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Ironwood Pharmaceuticals Reports Third Quarter 2026 Results and Raises Full-Year Guidance Driven by LINZESS Growth

Nov 5, 2026

8-K

Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer

Oct 16, 2026

8-K

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Following Strong Q2 Results

Aug 6, 2026

8-K

Ironwood Pharmaceuticals Announces Results of 2026 Annual Meeting of Stockholders

Jun 18, 2026

8-K

Ironwood Pharmaceuticals Repays $200 Million in Convertible Senior Notes

Jun 15, 2026

8-K/A

Interim CFO Ronald Silver receives monthly fee and 25,000 RSUs for new role, vesting over two years.

May 21, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B2

Form 424B2 - Prospectus [Rule 424(b)(2)]

Feb 12, 2014

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Feb 10, 2014

424B2

Form 424B2 - Prospectus [Rule 424(b)(2)]

May 22, 2013

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

May 20, 2013

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Feb 10, 2012

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Feb 8, 2012

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Nov 5, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Nov 9, 2023

S-3ASR

SHELF

Nov 9, 2023

SC TO-T/A

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]

Jun 29, 2023

SC TO-T/A

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]

Jun 26, 2023

SC TO-T/A

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]

Jun 20, 2023

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

BANK OF AMERICA CORP /DE/ (Filed by)

Oct 28, 2026

144

Form 144 - Report of proposed sale of securities

Sep 23, 2026

DENNER ALEXANDER J (Reporting)

Sep 17, 2026

SCHEDULE 13G/A

ARMISTICE CAPITAL, LLC (Filed by)

Aug 14, 2026

SCHEDULE 13G

STATE STREET CORP (Filed by)

Aug 7, 2026

SCHEDULE 13G/A

BlackRock, Inc. (Filed by)

Jul 28, 2026

Other

TYPE

HEADLINE

FILED AT

LETTER

Form UPLOAD - SEC-generated letter

Dec 6, 2023

CORRESP

Form CORRESP - Correspondence

Nov 30, 2023

LETTER

Form UPLOAD - SEC-generated letter

Nov 15, 2023

CT ORDER

Form CT ORDER - Confidential treatment order

Apr 26, 2019

CT ORDER

Form CT ORDER - Confidential treatment order

Apr 26, 2019

CT ORDER

Form CT ORDER - Confidential treatment order

Mar 19, 2019

Ironwood Pharmaceuticals, Inc. IRWD · SEC Filings